financetom
Business
financetom
/
Business
/
MEG Energy Board Recommends Shareholders Reject Strathcona's Takeover Bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MEG Energy Board Recommends Shareholders Reject Strathcona's Takeover Bid
Jun 16, 2025 6:15 AM

08:39 AM EDT, 06/16/2025 (MT Newswires) -- MEG Energy ( MEGEF ) said Monday that its board recommended that shareholders reject Strathcona Resources' ( STHRF ) unsolicited takeover bid.

MEG's board said Strathcona's bid was "inadequate, opportunistic, and not in the best interests of MEG or its shareholders."

In late May, Strathcona offered to acquire the MEG shares it does not already own for a combination of 0.62 of a Strathcona share and $4.10 in cash apiece. The offer remains open until Sept. 15.

"Strathcona's offer is inadequate by all reasonable measures and is not the right path forward for MEG shareholders," said James McFarland, MEG's chairman.

The company said MEG shareholders should take no action and not tender their shares to Strathcona's offer.

"A combination with Strathcona would expose shareholders to inferior assets and significant capital markets risks, including a $6 billion overhang resulting from Waterous Energy Fund's 51% ownership in the combined company, which would allow WEF investors to realize liquidity over time," McFarland said.

MEG's share price rose 1.1% on Friday to $26.09 on the TSX.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK blood cancer drug nearly halves risk of death in late-stage trial
GSK blood cancer drug nearly halves risk of death in late-stage trial
Jun 2, 2024
June 2 (Reuters) - GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday. In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in...
Pre-surgery treatment with Bristol Myers combination therapy  leads to better skin cancer outcomes
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Jun 2, 2024
June 2 (Reuters) - Treatment with Bristol Myers Squibb's ( BMY ) immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday. The study of 423 patients with...
OPEC+ agrees to extend voluntary output cuts into Q3'24, talks continue, sources say
OPEC+ agrees to extend voluntary output cuts into Q3'24, talks continue, sources say
Jun 2, 2024
LONDON (Reuters) - OPEC+ has agrees to extend voluntary oil production cuts of 2.2 million barrels per day into the third quarter of 2024, two OPEC+ sources said on Sunday. Talks about cuts for the fourth quarter and 2025 continue, the sources said. (Reporting by OPEC Newsroom; Editing by Emelia Sithole-Matarise) ...
Next Boeing CEO should understand past mistakes, airlines boss says
Next Boeing CEO should understand past mistakes, airlines boss says
Jun 2, 2024
DUBAI, June 2 (Reuters) - The next Boeing ( BA ) CEO should have an understanding of what led up to its current crisis and be prepared to look outside for examples of best industrial practices, the head of the International Air Transport Association said on Sunday. It is not for me to say who should be running Boeing (...
Copyright 2023-2025 - www.financetom.com All Rights Reserved